These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 26754826)
1. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply. Bernal T; Martínez-Camblor P; Sánchez-García J; Sanz G Leukemia; 2016 Mar; 30(3):740-1. PubMed ID: 26754826 [No Abstract] [Full Text] [Related]
2. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry. Dinmohamed AG; van Norden Y; Visser O; Posthuma EF; Huijgens PC; Sonneveld P; van de Loosdrecht AA; Jongen-Lavrencic M Leukemia; 2015 Dec; 29(12):2449-51. PubMed ID: 26369829 [No Abstract] [Full Text] [Related]
3. Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile. Breccia M; Voso MT; Maurillo L; Niscola P; Fianchi L; Aloe Spiriti MA; Buccisano F; Latagliata R; Pelliccia S; Fenu S; Tendas A; Alimena G Am J Hematol; 2014 May; 89(5):565. PubMed ID: 24458879 [No Abstract] [Full Text] [Related]
4. Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience. Kantarjian HM J Clin Oncol; 2002 May; 20(10):2415-6. PubMed ID: 12011118 [No Abstract] [Full Text] [Related]
5. [Cost-effectiveness analysis of azacitidine for myelodysplastic syndromes in Japan]. Tomonaga M; Kamae I Rinsho Ketsueki; 2012 Mar; 53(3):310-7. PubMed ID: 22499047 [TBL] [Abstract][Full Text] [Related]
6. 5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3. Breccia M; Cannella L; Santopietro M; Loglisci G; Federico V; Salaroli A; Nanni M; Mancini M; Alimena G Leukemia; 2011 Apr; 25(4):736-7. PubMed ID: 21293489 [No Abstract] [Full Text] [Related]
7. 5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment. Breccia M; Salaroli A; Loglisci G; Martelli M; D'Elia GM; Nanni M; Mauro FR; Alimena G Leuk Res; 2011 Oct; 35(10):1409-11. PubMed ID: 21680017 [TBL] [Abstract][Full Text] [Related]
8. Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes. Liapis K; Papadopoulos V; Vrachiolias G; Galanopoulos AG; Papoutselis M; Papageorgiou SG; Diamantopoulos PT; Pappa V; Viniou NA; Kourakli A; Τsokanas D; Vassilakopoulos TP; Hatzimichael E; Bouronikou E; Ximeri M; Pontikoglou C; Megalakaki A; Zikos P; Panayiotidis P; Dimou M; Karakatsanis S; Papaioannou M; Vardi A; Kontopidou F; Harchalakis N; Adamopoulos I; Symeonidis A; Kotsianidis I Blood Cancer J; 2021 Feb; 11(2):30. PubMed ID: 33574231 [No Abstract] [Full Text] [Related]
9. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine. Kamiya T; Nakazato T Med Oncol; 2019 Jan; 36(3):25. PubMed ID: 30706221 [No Abstract] [Full Text] [Related]
11. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes. Fenaux P; Ades L Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796 [TBL] [Abstract][Full Text] [Related]
12. Is there an association between 5-azacitidine and ototoxicity? Malik A; Misbah S; Spaccavento C; Yudelman I J Clin Pharmacol; 2010 Sep; 50(9):1056-7. PubMed ID: 20234015 [No Abstract] [Full Text] [Related]
13. Azacitine (vidaza) for myelodysplastic syndrome. Med Lett Drugs Ther; 2005 Jan; 47(1201):11. PubMed ID: 15678015 [TBL] [Abstract][Full Text] [Related]
14. Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome? Alessandrino EP; Della Porta MG; Pascutto C; Bacigalupo A; Rambaldi A J Clin Oncol; 2013 Jul; 31(21):2761-2. PubMed ID: 23775971 [No Abstract] [Full Text] [Related]
15. Neutrophilic panniculitis following azacitidine treatment for myelodysplastic syndromes. Kim IH; Youn JH; Shin SH; Yahng SA; Lee SE; Kwon JC; Lee DG; Park KS; Choi MH; Jung SE; Kim YJ Leuk Res; 2012 Jul; 36(7):e146-8. PubMed ID: 22483068 [No Abstract] [Full Text] [Related]
16. Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine. Gangatharan SA; Carney DA; Campbell LJ; Prince HM; Kenealy MK; Seymour JF Eur J Haematol; 2011 Aug; 87(2):186-8. PubMed ID: 21623918 [No Abstract] [Full Text] [Related]
17. [Pharmacological profiles and clinical roles of 5-azacitidine (Vidaza(®) for injection 100 mg) for the treatment of myelodysplastic syndrome (MDS)]. Takahashi Y; Kimura S; Okano M Nihon Yakurigaku Zasshi; 2012 Nov; 140(5):235-43. PubMed ID: 23138323 [No Abstract] [Full Text] [Related]
18. Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis. Kumar A; List AF; Hozo I; Komrokji R; Djulbegovic B Haematologica; 2010 Feb; 95(2):340-2; author reply 343-4. PubMed ID: 19850902 [No Abstract] [Full Text] [Related]
19. Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure. Prébet T; Thepot S; Gore SD; Dreyfus F; Fenaux P; Vey N Haematologica; 2013 Feb; 98(2):e18-9. PubMed ID: 22983576 [No Abstract] [Full Text] [Related]